未登录

C

C. K. Chan

University of Hong Kong

H指数:23

被引数:1,527

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A nurse-delivered brief health education intervention to improve pneumococcal vaccination rate among older patients with chronic diseases: A cluster randomized controlled trial

INTERNATIONAL JOURNAL OF NURSING STUDIES

IF7.1

2015-01-0119

OAAI

Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA

GASTROENTEROLOGY

IF25.1

2014-05-01135

OAAI

TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUS-INFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE

JOURNAL OF HEPATOLOGY

IF33

2013-04-011

OAAI

SUSTAINED VIROLOGICAL RESPONSE INDUCED BY TREATMENT OF HEPATITIS C IS ASSOCIATED WITH IMPROVEMENT IN INSULIN RESISTANCE

JOURNAL OF HEPATOLOGY

IF33

2012-04-010

PREAI

Prevalence and time trend of intestinal metaplasia in Hong Kong

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2009-05-1816

PREAI

One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2008-07-0723

OAAI

Symptom resolution does not predict healing of erosive oesophagitis in Chinese

症状消退不能预测中国人糜烂性食管炎的愈合

IF3.6

2007-07-3110

PREAI

Clinical trial:: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2007-07-2618

OAAI

Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy

IF3.6

2006-07-2827

PREAI

Colonoscopy demand and practice in a regional hospital over 9 years in Hong Kong: Resource implication for cancer screening

IF3.6

2006-07-2813

PREAI

Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2006-01-1658

OAAI

Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2005-07-2971

OAAI

Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2005-05-267

PREAI

Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2004-12-2222

OAAI

A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2003-10-1772

PREAI

Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance

CLINICAL INFECTIOUS DISEASES

IF7.3

2003-10-0132

OAAI

Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users -: a randomized trial

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2003-09-3055

PREAI

An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2003-07-0161

PREAI

Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population

IF5.1

2003-04-3053

OAAI

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2003-03-05100

PREAI